English, Article edition: Hepatitis C Screening and Treatment versus Liver Transplantation: A Financial Option Appraisal and Commissioning Model for Purchasers Nevil Batra

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/92325
Physical Description
  • article
Language
  • English

Edition details

Title
  • Hepatitis C Screening and Treatment versus Liver Transplantation: A Financial Option Appraisal and Commissioning Model for Purchasers
Author
  • Nevil Batra
Physical Description
  • article
Notes
  • Objectives: To: 1. calculate the number needed to screen (NNS) and community effectiveness of combination treatment (interferon-alpha plus ribavirin) compared with its efficacy of 28 to 45%; 2. compare the cost of opportunistic hepatitis C virus (HCV) screening and combined treatment to prevent 1 high risk patient developing cirrhosis with the cost of liver transplantation; and 3. put a cash value on how much purchasing authorities should bid in a commissioning round for new HCV treatments. Design: 1. A financial option appraisal of liver transplantation versus opportunistic HCV screening and treatment; 2. a financial/​commissioning model from a purchaser's perspective using the latest national and international standards/​guidelines and audit reports. Setting and participants: West Kent Health Authority (963 000 residents and 9 primary care groups). All patients at high risk of HCV presenting to health services in 1998/​1999 who had an anti-HCV test. Results: Using current National Institute of Clinical Excellence (NICE) guidance (combined treatment for moderate to severe liver changes), about 113 479 high risk persons need to be screened and medically treated, costing about 50 947 pounds sterling (Lstg ) to prevent 1 patient developing cirrhosis in 10 to 20 years. The community effectiveness therefore is 0.00088%. The net present value (NPV) of HCV screening and combined treatment is -Lstg 32 471 to -Lstg 25 407 to prevent 1 patient developing cirrhosis compared with liver transplantation; and the marginal cost to fund current volumes is Lstg 54 000. In contrast, if current international standards were used (which advocates combined treatment for mild, moderate and severe liver changes), the NNS is 118 to prevent 1 high risk patient developing cirrhosis; the community effectiveness is 0.847%; the NPV is -Lstg 6479 to Lstg 584; and the variable cost to fund current volumes is Lstg 796 850. Conclusion: The community effectiveness of combined treatment, at best (i.e. using the international model), is 33 to 53 times less than its efficacy; HCV screening and drug treatment is more expensive than liver transplantation. Furthermore, the international model is a far more technically efficient pathway for delivering HCV care than that recommended by NICE guidance.
  • Cost effectiveness, Hepatitis C, Hepatitis C, Interferon alpha, Liver transplant, Ribavirin
  • RePEc:wkh:dmhout:v:9:y:2001:i:7:p:371-384
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment